What is claimed is:

1. A compound selected from the group represented by Formula I:

$$\begin{array}{c|c}
 & R_1 \\
 & R_2 \\
 & R_{2'} \\
 & R_{7}
\end{array}$$

Formula I

wherein:

T and T' are independently a covalent bond or optionally substituted lower alkylene;

R₁ is hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, or optionally substituted heteroaralkyl-;

 R_2 and R_2 are independently hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; or R_2 and R_2 taken together form an optionally substituted 3- to 7-membered ring which optionally incorporates from one to two heteroatoms, selected from N, O, and S in the ring;

 R_3 is hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, optionally substituted heteroaryl-, $C(O)-R_6$, or $C(O)-R_6$, or

 R_6 is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, R_4O - or R_5 -NH-;

R_{6a} is optionally substituted alkyl, optionally substituted aryl, optionally substituted alkylaryl, optionally substituted heteroaryl, optionally substituted

alkylheteroaryl, or R5-NH-;

R₇ is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;

or R₇ taken together with R₃, and the nitrogen to which they are bound, form an optionally substituted 5- to 12-membered nitrogen-containing heterocycle, which optionally incorporates from one to two additional heteroatoms, chosen from N, O, and S in the heterocycle ring;

or R₇ taken together with R₂ form an optionally substituted 5- to 12-membered nitrogen-containing heterocycle, which optionally incorporates from one to two additional heteroatoms, chosen from N, O, and S in the heterocycle ring;

R₄ is optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; and

R₅ is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;

(Formula I including single stereoisomers and mixtures of stereoisomers);

- a pharmaceutically acceptable salt of a compound of Formula I;
- a pharmaceutically acceptable solvate of a compound of Formula I; or
- a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of a compound of Formula I.
- 2. A compound of claim 1 comprising one or more of the following:

one of T and T' is a covalent bond and the other is a covalent bond or optionally substituted lower alkylene;

R₁ is optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aralkyl;

 R_2 is optionally substituted C_1 - C_4 alkyl;

R₂, is hydrogen or optionally substituted C₁-C₄ alkyl;

 R_3 is $-C(O)R_6$;

R₆ is optionally substituted C₁-C₈ alkyl, optionally substituted aryl-C₁-C₄-

alkyl-, optionally substituted heteroaryl- C_1 - C_4 -alkyl-, optionally substituted heteroaryl, optionally substituted aryl, R_{11} O- or R_{12} -NH-;

R₁₁ is optionally substituted C₁-C₈ alkyl or optionally substituted aryl;

 R_{12} is hydrogen, optionally substituted C_1 - C_8 alkyl or optionally substituted aryl; and

 R_7 is hydrogen, optionally substituted C_1 - C_{13} alkyl, optionally substituted aryl, optionally substituted aryl- C_1 - C_4 -alkyl-, optionally substituted heterocyclyl, or optionally substituted heteroaryl- C_1 - C_4 -alkyl-.

3. A compound of claim 2 comprising one or more of the following: T and T' are each a covalent bond;

R₁ is ethyl, propyl, methoxyethyl, naphthyl, phenyl, bromophenyl, chlorophenyl, methoxyphenyl, ethoxyphenyl, tolyl, dimethylphenyl, chorofluorophenyl, methylchlorophenyl, ethylphenyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, hydroxybenzyl, dichlorobenzyl, dimethoxybenzyl, naphthylmethyl, or (ethoxycarbonyl)ethyl;

R₂ is methyl, ethyl, propyl, butyl, methylthioethyl, methylthiomethyl, aminobutyl, (CBZ)aminobutyl, cyclohexylmethyl, benzyloxymethyl, methylsulfinylethyl, methylsulfinylmethyl, or hydroxymethyl;

R₂, is hydrogen;

 R_6 is optionally substituted C_1 - C_8 alkyl, optionally substituted aryl- C_1 - C_4 -alkyl-, optionally substituted heteroaryl- C_1 - C_4 -alkyl-, optionally substituted heteroaryl, or optionally substituted aryl; and

R₇ is hydrogen, C₁-C₄ alkyl; cyclohexyl; phenyl substituted with hydroxyl, C₁-C₄ alkoxy or C₁-C₄ alkyl; benzyl; or R₁₆-alkylene-, wherein R₁₆ is hydroxyl, carboxy, (C₁-C₄ alkoxy)carbonyl-, di(C₁-C₄ alkyl)amino-, (C₁-C₄ alkyl)amino-, amino, (C₁-C₄ alkoxy)carbonylamino-, C₁-C₄ alkoxy-, or optionally substituted N-heterocyclyl-.

4. A compound of claim 3 comprising one or more of the following:

R₁ is ethyl, propyl, methoxyethyl, naphthyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, hydroxybenzyl, dichlorobenzyl, dimethoxybenzyl, naphthylmethyl, or (ethoxycarbonyl)ethyl;

R₂ is ethyl or propyl;

R₆ is optionally substituted phenyl; and

 R_7 is R_{16} -alkylene-, wherein R_{16} is amino, C_1 - C_4 alkylamino-, C_1 - C_4 alkoxy-, hydroxyl, or N-heterocyclyl.

5. A compound of claim 4 comprising one or more of the following:

 R_1 is benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, or hydroxybenzyl;

R₂ is i-propyl; and

methylhalophenyl, hydroxymethyl-phenyl, is halophenyl, R_6 tolyl, halo(trifluoromethyl)phenyl-, methylenedioxyphenyl, formylphenyl or cyanophenyl; R₇ is aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylaminoethyl, methylaminopropyl, methylaminobutyl, methylaminopentyl, methylaminohexyl, dimethylaminoethyl, dimethylaminopropyl, dimethylaminobutyl, dimethylaminopentyl, ethylaminoethyl, ethylaminopropyl, ethylaminobutyl, dimethylaminohexyl, diethylaminopropyl, diethylaminoethyl, ethylaminohexyl, ethylaminopentyl, diethylaminobutyyl, diethylaminopentyl, or diethylaminohexyl.

- 6. A compound of claim 5 wherein R_1 is benzyl.
- 7. A compound of claim 1 comprising one or more of the following:

one of T and T' is a covalent bond and the other is a covalent bond or optionally substituted lower alkylene;

R₁ is optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aralkyl;

R₂ is optionally substituted C₁-C₄ alkyl;

 R_{2} is hydrogen or optionally substituted $C_{1}\text{-}C_{4}$ alkyl; and

R₇ taken together with R₃, and the nitrogen to which they are bound, form an optionally substituted 5- to 12-membered nitrogen-containing heterocycle, which optionally incorporates from one to two additional heteroatoms, chosen from N, O, and S in the heterocycle ring.

8. A compound of claim 7 comprising one or more of the following:

T and T' are each a covalent bond;

R₁ is ethyl, propyl, methoxyethyl, naphthyl, phenyl, bromophenyl, chlorophenyl, methoxyphenyl, ethoxyphenyl, tolyl, dimethylphenyl, chorofluorophenyl, methylchlorophenyl, ethylphenyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, hydroxybenzyl, dichlorobenzyl, dimethoxybenzyl, naphthylmethyl, or (ethoxycarbonyl)ethyl;

R₂ is methyl, ethyl, propyl, butyl, methylthioethyl, methylthiomethyl, aminobutyl, (CBZ)aminobutyl, cyclohexylmethyl, benzyloxymethyl, methylsulfinylethyl, or hydroxymethyl;

R_{2'} is hydrogen; and

R₃ taken together with R₇ and the nitrogen to which they are bound, forms an optionally substituted imidazolyl ring.

9. A compound of claim 7 comprising one or more of the following:

T and T' are each a covalent bond;

R₁ is ethyl, propyl, methoxyethyl, naphthyl, phenyl, bromophenyl, chlorophenyl, methoxyphenyl, ethoxyphenyl, tolyl, dimethylphenyl, chorofluorophenyl, methylchlorophenyl, ethylphenyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, hydroxybenzyl, dichlorobenzyl, dimethoxybenzyl, naphthylmethyl, or (ethoxycarbonyl)ethyl;

R₂ is methyl, ethyl, propyl, butyl, methylthioethyl, methylthiomethyl, aminobutyl, (CBZ)aminobutyl, cyclohexylmethyl, benzyloxymethyl, methylsulfinylethyl, or hydroxymethyl;

R₂ is hydrogen; and

R₃ taken together with R₇, and the nitrogen to which they are bound, forms an optionally substituted imidazolinyl ring.

10. A compound of claim 7 comprising one or more of the following:

T and T' are each a covalent bond;

R₁ is ethyl, propyl, methoxyethyl, naphthyl, phenyl, bromophenyl, chlorophenyl, methoxyphenyl, ethoxyphenyl, tolyl, dimethylphenyl, chorofluorophenyl, methylchlorophenyl, ethylphenyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, hydroxybenzyl, dichlorobenzyl,

dimethoxybenzyl, naphthylmethyl, or (ethoxycarbonyl)ethyl;

R₂ is methyl, ethyl, propyl, butyl, methylthioethyl, methylthiomethyl, aminobutyl, (CBZ)aminobutyl, cyclohexylmethyl, benzyloxymethyl, methylsulfinylethyl, methylsulfinylmethyl, or hydroxymethyl;

R₂, is hydrogen; and

R₃ taken together with R₇ forms an optionally substituted piperazine- or diazepam ring.

11. A compound of any of claim 7-10 comprising one or more of the following:

R₁ is ethyl, propyl, methoxyethyl, naphthyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, hydroxybenzyl, dichlorobenzyl, dimethoxybenzyl, naphthylmethyl, or (ethoxycarbonyl)ethyl; and

 R_2 is ethyl or propyl.

12. A compound of claim 11 comprising one or more of the following

 R_1 is benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, or hydroxybenzyl; and

R₂ is i-propyl.

- 13. A compound of claim 12 wherein R_1 is benzyl.
- 14. A compound of claim 1 wherein

T and T' are each a covalent bond;

 R_1 is benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, or hydroxybenzyl;

R₂, is hydrogen;

 R_2 is optionally substituted C_1 - C_4 alkyl;

 R_3 is $-C(O)R_6$;

R₆ is optionally substituted phenyl;

R₇ is R₁₆-alkylene-; and

R₁₆ is amino, C₁-C₄ alkylamino-, di(C₁-C₄ alkyl)amino-, C₁-C₄ alkoxy-, hydroxyl, or N-heterocyclyl.

15. A compound of claim 1 wherein

T and T' are each a covalent bond;

R₁ is benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, or hydroxybenzyl;

R₂, is hydrogen;

R₂ is optionally substituted C₁-C₄ alkyl; and

R₇ taken together with R₃, and the nitrogen to which they are bound, form an optionally substituted 5- to 12-membered nitrogen-containing heterocycle, which optionally incorporates from one to two additional heteroatoms, chosen from N, O, and S in the heterocycle ring.

- 16. A compound of claim 1 that is N-(3-amino-propyl)-N-[1-(4-benzyl-5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-2-methyl-propyl]-4-methyl-benzamide, or a pharmaceutically acceptable salt, solvate of a compound of Formula I; or solvate of a salt thereof.
- 17. A compound of any of the above claims wherein the stereogenic center to which R_2 and R_2 , is attached is of the R configuration.
- 18. A composition comprising a pharmaceutical excipient and a compound of any one of claims 1-16.
- 19. A composition according to claim 18, wherein said composition further comprises a chemotherapeutic agent other than a compound of Formula I.
- 20. A composition according to claim 19 wherein said chemotherapeutic agent is a taxane, a vinca alkaloid, or a topoisomerase I inhibitor.
- 21. A method of modulating KSP kinesin activity which comprises contacting said kinesin with an effective amount of a compound according to any one of claims 1 to 16.

22. A method of inhibiting KSP which comprises contacting said kinesin with an effective amount of a compound according to any one of claims 1 to 16.

- 23. A method for the treatment of a cellular proliferative disease comprising administering to a patient in need thereof a compound according to any one of claims 1-16.
- 24. A method for the treatment of a cellular proliferative disease comprising administering to a patient in need thereof a composition according to any one of claims 18-20.
- 25. A method according to claim 23 or claim 24 wherein said disease is selected from cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, and inflammation.
- 26. The use, in the manufacture of a medicament for treating cellular proliferative disease, of a compound according to any one of claims 1-16.
- 27. The use of a compound as defined in claim 26 for the manufacture of a medicament for treating a disorder associated with KSP kinesin activity.